O Celecoxib, antiinflamatório não esteroidal, inibidor seletivo da COX-2, tem se mostrado um importante agente anticarcinogênico, mas o seu papel no carcinoma epidermóide de boca (CEB) não é totalmente compreendido. Sabe-se que diversas alterações genéticas estão associadas à patogênese do CEB, a neoplasia maligna mais comum de cabeça e pescoço. Algumas dessas alterações comprometem proteínas pertencentes à via de sinalização do Akt, envolvida em diferentes fenômenos celulares. É sabido que Akt pode ativar o fator de transcrição NF-kB, o qual tem importante participação na fisiologia normal e no câncer. A proteína COX-2, descrita inicialmente em processos inflamatórios, está associada com a oncogênese e recentemente tem sido associada com a via de sinalização do Akt e com o NF-kB. Portanto, o objetivo deste estudo foi analisar o efeito do Celecoxib sobre linhagens celulares de carcinoma epidermóide de boca e verificar a localização intracelular e a expressão das proteínas pAkt, NF-kB e COX-2 em linhagens celulares de carcinoma epiermóide de boca após o tratamento com o Celecoxib.Através da técnica de imunofluorescência, foram analisados os padrões de expressão das proteínas pAkt, NFkB e COX-2 em quatro linhagens celulares de carcinoma epidermóide bucal submetidas ao tratamento com Celecoxib, cuja a dose e o tempo foram obtidos a partir de ensaios de viabilidade celular. Também se realizou ensaio de apoptose celular. Como controle utilizou-se células não tratadas com o medicamento. O Celecoxib na dose de 30 M por 24 horas causa apoptose.Na técnica de western blot, somente a linhagem SCC15 apresentou uma diminuição significativa para a COX-2. Entretanto, para p-Akt e NF-kB nenhuma alteração na expressão foi observada entre os grupos controle e tratado.Na imunofluorescência, houve alteração no padrão de expressão das proteínas pAkt, NF-kB e COX-2, quando se comparou os grupos contrele e tratado. Portanto, o Celecoxib pode ser um eficaz agente terapêutico, uma vez que demonstrou grande eficácia na inibição da proliferação celular de linhagens celulares de CEB. / Celecoxib, nonsteroidal anti-inflammatory COX-2 selective inhibitor, has proven to be an important anticancer agent. However its role in oral squamous cell carcinoma (OSCC) is not entirely understood. This is the most common malignancy of head and neck regionand it is known that various genetic alterations are associated with its pathogenesis. Some of these changes affect proteins belonging to the Akt signaling pathway, involved in different cellular processes. It is known that Akt can activate the transcription factor NF-kB, which has important role in normal physiology and cancer.The COX-2 proteinwas firstly described in the inflammatory processes, is associated with oncogenesis and has recently been related with the Akt signaling pathwayand with NF-kB. Therefore, the aim of this study was to analyze the effect of Celecoxib on squamous cell carcinoma cell lines and to determine pAkt, NF-kB and COX-2 intracellular localization and levels of expressionin this cell lines after treated with Celecoxib. By immunofluorescence, we analyzed the pAkt, NF-kB and COX-2 expression patterns in four oral squamous cell carcinoma cell lines treated with Celecoxib, which the dose and time were obtained from cell viability assays. Cellular apoptosis assay was also performed. As control the cells were not treated with this drug. Celecoxibcauses apoptosisin the dose of 30 M for 24 hours. In the western blottechnique, only the SCC15 cell line shows a significant decrease for COX-2. However, for p-Akt and NF-kB no change in expression was observed between control and treated groups. On immunofluorescence, there were changes in the pAkt, NFkB and COX-2protein expression pattern when the control group was compared with treated group. Therefore, the Celecoxib can be an effective therapeutic agent, since it has shown great efficacy in thecelular proliferation inhibition of the OSCC cell lines.

A doença de Parkinson (DP) é a segunda doença neurodegenerativa que mais atinge a população mundial. O desenvolvimento dos prejuízos motores decorrentes da doença está relacionado a sua fisiopatologia, que promove principalmente a neurodegeneração dos neurônios dopaminérgicos da substância negra pars compacta. Estudos sugerem o envolvimento de vias inflamatórias exacerbando a morte celular na fisiopatologia da DP. O fenômeno neuroinflamatório é caracterizado pela ativação de diversas células do sistema nervoso central, como neurônios, micróglia e astrócitos, além dos principais mediadores pró- inflamatórios, que são a enzima ciclooxigenase-2 (COX-2), o fator de necrose tumoral-alfa (TNF-?), a interleucina 1? (IL-1?) e a interleucina 6 (IL-6), entre outros. Estes fatores estão presentes em estruturas neuroanatômicas como o estriado e substância negra pars compacta de indivíduos com a DP. O tratamento crônico com L-DOPA, o precursor do neurotransmissor dopamina, inicialmente gera uma redução da manifestação dos sintomas motores na maioria dos pacientes. Porém, após certo tempo de tratamento, ocorre o surgimento de complicações motoras, como a discinesia induzida por L-DOPA (LID - LDOPA-induced dyskinesia). O desenvolvimento e a manifestação da LID também podem acompanhar uma resposta inflamatória anormal. Dados do grupo sugerem a enzima COX-2 e as células gliais como mediadores da LID. Estudos apontam que fármacos que reduzem a LID modulam a expressão de COX-2. Nosso objetivo, portanto, foi caracterizar a presença de fatores/mecanismos pró-inflamatórios no estriado lesionado de camundongos tratados com LDOPA. Nossos resultados serão apresentados em três capítulos. No primeiro capítulo, empregamos o modelo de camundongos hemiparkinsonianos (lesionados com 6- hidroxidopamina) e tratamos com L-DOPA por diferentes períodos de tempo (1, 7, 14 e 21 dias) para analisarmos o surgimento de fatores inflamatórios no estriado, como a enzima COX-2, o fator nuclear kappa-B (NF-?B) e a expressão e atividade dos astrócitos e micróglia. No segundo capítulo, demonstramos o potencial destas células gliais em produzir citocinas e/ou glutamato após estímulo com os principais neurotransmissores envolvidos com a LID, a DA (ou seu precursor L-DOPA) e glutamato. No terceiro capítulo, demonstramos o potencial terapêutico de drogas usadas na clínica - com propriedades anti-inflamatórias - de reduzirem a LID previamente estabelecida. Para tal, utilizamos o canabidiol (princípio ativo da Cannabis, usado no tratamento para epilepsia, entre outros) e o celecoxibe (inibidor específico da atividade enzimática da COX-2). Este estudo corrobora a existência de um processo inflamatório no estriado lesionado de camundongos parkinsonianos, exacerbado pelo tratamento com L-DOPA. A enzima COX-2 pode ter um papel fundamental no desenvolvimento da LID. Adicionalmente, este trabalho sugere que drogas utilizadas clinicamente com ação anti-inflamatória podem se tornar possíveis ferramentas terapêuticas para a redução desta desordem. Desta forma, relacionamos a produção de fatores inflamatórios e a ativação de células gliais à perpetuação de uma atividade pós-sináptica estriatal anormal que ocasionam a \"má plasticidade\" típica da LID. / Parkinson\'s disease (PD) is the second most common neurodegenerative disease in world population. The development of motor impairments related to this disease occurs due to its pathophysiology, which mainly promotes the neurodegeneration of the dopaminergic neurons in the substantia nigra pars compacta. Studies suggest the involvement of inflammatory pathways that exacerbate cell death in the pathophysiology of PD. The neuroinflammatory phenomenon is characterized by the activation of central nervous system cells, such as neurons, microglia and astrocytes, in addition to proinflammatory mediators that are elevated in patients with PD, such as the enzyme cyclooxygenase-2 (COX-2), tumor necrosis factoralpha (TNF-?), interleukin 1? (IL-1?) and interleukin-6 (IL-6), among others. These factors are present in neuroanatomic structures such as striatum and substantia nigra pars compacta. Chronic treatment with L-DOPA, the precursor of the neurotransmitter dopamine, initially generates a reduction in the manifestation of motor symptoms in the vast majority of patients, but after a certain time of treatment, motor complications begin to appear, such as L-DOPAinduced dyskinesia (LID). The development and manifestation of LID may also accompany an abnormal inflammatory response. Data from our group suggest the enzyme COX-2 as one of the mediators of LID. Studies also point out that drugs that reduce LID are able to modulate COX-2 expression. Our objective, therefore, was to characterize the presence of proinflammatory factors/mechanisms in the injured striatum of mice treated with L-DOPA. For this purpose, the present study will be divided into three chapters. In the first chapter, we used the hemiparkinsonian mice model (lesioned with 6-hydroxydopamine) treated with LDOPA for different time periods (1, 7, 14 and 21 days) to observe the appearance of inflammatory factors in the striatum, such as the COX-2 enzyme, nuclear factor kappa-B (NF- ?B) and the expression and activity of glial cells, represented by astrocytes and microglia. In the second chapter, we demonstrated the potential of glial cells to produce cytokines and/or glutamate after stimulation with the major neurotransmitters involved with LID, dopamine (or its precursor L-DOPA) and glutamate. Finally, in the third chapter, we demonstrate the therapeutic potential of drugs used in the clinic with anti-inflammatory properties to reduce previously established LID. For this, we used cannabidiol (the active constituent of Cannabis, used for the treatment of epilepsy, among others) and celecoxib (a specific COX-2 activity inhibitor). The present study corroborates the existence of an inflammatory process in the injured striatum of parkinsonian mice, exacerbated by treatment with L-DOPA. The COX-2 enzyme may play a key role in the development of LID. Additionally, this work suggests that drugs clinically used with anti-inflammatory action may become possible therapeutic tools for the reduction of this disorder. In this way, we relate the production of inflammatory factors and the activation of glial cells to the perpetuation of an abnormal striatal postsynaptic activity that causes the \"maladaptative plasticity\" typical of LID.

A doença de Parkinson (DP) é a segunda doença neurodegenerativa que mais atinge a população mundial. O desenvolvimento dos prejuízos motores decorrentes da doença está relacionado a sua fisiopatologia, que promove principalmente a neurodegeneração dos neurônios dopaminérgicos da substância negra pars compacta. Estudos sugerem o envolvimento de vias inflamatórias exacerbando a morte celular na fisiopatologia da DP. O fenômeno neuroinflamatório é caracterizado pela ativação de diversas células do sistema nervoso central, como neurônios, micróglia e astrócitos, além dos principais mediadores pró- inflamatórios, que são a enzima ciclooxigenase-2 (COX-2), o fator de necrose tumoral-alfa (TNF-?), a interleucina 1? (IL-1?) e a interleucina 6 (IL-6), entre outros. Estes fatores estão presentes em estruturas neuroanatômicas como o estriado e substância negra pars compacta de indivíduos com a DP. O tratamento crônico com L-DOPA, o precursor do neurotransmissor dopamina, inicialmente gera uma redução da manifestação dos sintomas motores na maioria dos pacientes. Porém, após certo tempo de tratamento, ocorre o surgimento de complicações motoras, como a discinesia induzida por L-DOPA (LID - LDOPA-induced dyskinesia). O desenvolvimento e a manifestação da LID também podem acompanhar uma resposta inflamatória anormal. Dados do grupo sugerem a enzima COX-2 e as células gliais como mediadores da LID. Estudos apontam que fármacos que reduzem a LID modulam a expressão de COX-2. Nosso objetivo, portanto, foi caracterizar a presença de fatores/mecanismos pró-inflamatórios no estriado lesionado de camundongos tratados com LDOPA. Nossos resultados serão apresentados em três capítulos. No primeiro capítulo, empregamos o modelo de camundongos hemiparkinsonianos (lesionados com 6- hidroxidopamina) e tratamos com L-DOPA por diferentes períodos de tempo (1, 7, 14 e 21 dias) para analisarmos o surgimento de fatores inflamatórios no estriado, como a enzima COX-2, o fator nuclear kappa-B (NF-?B) e a expressão e atividade dos astrócitos e micróglia. No segundo capítulo, demonstramos o potencial destas células gliais em produzir citocinas e/ou glutamato após estímulo com os principais neurotransmissores envolvidos com a LID, a DA (ou seu precursor L-DOPA) e glutamato. No terceiro capítulo, demonstramos o potencial terapêutico de drogas usadas na clínica - com propriedades anti-inflamatórias - de reduzirem a LID previamente estabelecida. Para tal, utilizamos o canabidiol (princípio ativo da Cannabis, usado no tratamento para epilepsia, entre outros) e o celecoxibe (inibidor específico da atividade enzimática da COX-2). Este estudo corrobora a existência de um processo inflamatório no estriado lesionado de camundongos parkinsonianos, exacerbado pelo tratamento com L-DOPA. A enzima COX-2 pode ter um papel fundamental no desenvolvimento da LID. Adicionalmente, este trabalho sugere que drogas utilizadas clinicamente com ação anti-inflamatória podem se tornar possíveis ferramentas terapêuticas para a redução desta desordem. Desta forma, relacionamos a produção de fatores inflamatórios e a ativação de células gliais à perpetuação de uma atividade pós-sináptica estriatal anormal que ocasionam a \"má plasticidade\" típica da LID. / Parkinson\'s disease (PD) is the second most common neurodegenerative disease in world population. The development of motor impairments related to this disease occurs due to its pathophysiology, which mainly promotes the neurodegeneration of the dopaminergic neurons in the substantia nigra pars compacta. Studies suggest the involvement of inflammatory pathways that exacerbate cell death in the pathophysiology of PD. The neuroinflammatory phenomenon is characterized by the activation of central nervous system cells, such as neurons, microglia and astrocytes, in addition to proinflammatory mediators that are elevated in patients with PD, such as the enzyme cyclooxygenase-2 (COX-2), tumor necrosis factoralpha (TNF-?), interleukin 1? (IL-1?) and interleukin-6 (IL-6), among others. These factors are present in neuroanatomic structures such as striatum and substantia nigra pars compacta. Chronic treatment with L-DOPA, the precursor of the neurotransmitter dopamine, initially generates a reduction in the manifestation of motor symptoms in the vast majority of patients, but after a certain time of treatment, motor complications begin to appear, such as L-DOPAinduced dyskinesia (LID). The development and manifestation of LID may also accompany an abnormal inflammatory response. Data from our group suggest the enzyme COX-2 as one of the mediators of LID. Studies also point out that drugs that reduce LID are able to modulate COX-2 expression. Our objective, therefore, was to characterize the presence of proinflammatory factors/mechanisms in the injured striatum of mice treated with L-DOPA. For this purpose, the present study will be divided into three chapters. In the first chapter, we used the hemiparkinsonian mice model (lesioned with 6-hydroxydopamine) treated with LDOPA for different time periods (1, 7, 14 and 21 days) to observe the appearance of inflammatory factors in the striatum, such as the COX-2 enzyme, nuclear factor kappa-B (NF- ?B) and the expression and activity of glial cells, represented by astrocytes and microglia. In the second chapter, we demonstrated the potential of glial cells to produce cytokines and/or glutamate after stimulation with the major neurotransmitters involved with LID, dopamine (or its precursor L-DOPA) and glutamate. Finally, in the third chapter, we demonstrate the therapeutic potential of drugs used in the clinic with anti-inflammatory properties to reduce previously established LID. For this, we used cannabidiol (the active constituent of Cannabis, used for the treatment of epilepsy, among others) and celecoxib (a specific COX-2 activity inhibitor). The present study corroborates the existence of an inflammatory process in the injured striatum of parkinsonian mice, exacerbated by treatment with L-DOPA. The COX-2 enzyme may play a key role in the development of LID. Additionally, this work suggests that drugs clinically used with anti-inflammatory action may become possible therapeutic tools for the reduction of this disorder. In this way, we relate the production of inflammatory factors and the activation of glial cells to the perpetuation of an abnormal striatal postsynaptic activity that causes the \"maladaptative plasticity\" typical of LID.

Le système immunitaire inné repose sur la détection de motifs microbiens et l'activation de réponses adaptées, parmi lesquelles les voies de signalisation dépendantes des facteurs NF-κB jouent un rôle primordial. Ces voies sont finement régulées afin d'éviter une réponse immunitaire excessive et soutenue dans le temps qui peut causer de nombreuses pathologies, comme les maladies auto-immunes et pro-inflammatoires. Au cours de ma thèse, j'ai élucidé certains mécanismes de régulation des voies de signalisation NF-κB, Toll et IMD, chez la drosophile, qui reposent sur l'ubiquitination de protéines et leur dégradation par la voie endocytaire ou le protéasome. L'ubiquitination réversible des protéines est une modification post-traductionnelle qui permet de réguler leur activité, leur stabilité et leur localisation subcellulaire. En particulier, l'ubiquitination des récepteurs membranaires peut servir de signal d'endocytose et de dégradation lysosomale. Chez la drosophile, le récepteur PGRP-LC reconnaît spécifiquement le peptidoglycane (PGN) bactérien de type acide diaminopimélique et induit la voie de signalisation IMD. J'ai montré que PGRP-LC est ubiquitiné, internalisé et dégradé par la voie endocytaire. Dans ce processus, j'ai identifié le rôle majeur de la déubiquitinase USP8 qui contrôle la dégradation de PGRP-LC ubiquitiné. J'ai aussi mis en évidence que la stimulation de la voie IMD par les PGN augmente l'internalisation et la dégradation de PGRP-LC, assurant l'élimination des récepteurs après que la voie IMD ait été activée. En outre, j'ai participé à des études visant à comprendre le rôle des déubiquitinases USP2, USP34 et USP36, préalablement sélectionnées par l'équipe comme des régulateurs négatifs des voies IMD et/ou Toll. Mes résultats ont notamment contribué à montrer que USP2 agit principalement au niveau de la protéine adaptatrice Imd, en permettant l'hydrolyse de ses chaînes d'ubiquitine K48 et sa dégradation par le protéasome. Finalement, j'ai observé que USP2 interagit également avec PGRP-LC et favorise l'hydrolyse des chaînes K48 associées à ce récepteur, bien que dans ce cas, la dégradation des formes poly-ubiquitinées K48 de PGRP-LC ne dépende pas du protéasome, mais des protéines de la voie endocytaire Hrs, Rab5 et de la déubiquitinase USP8. / The innate immune system relies on the recognition of “non-self” and on the activation of adapted responses, among which NF-κB signaling pathways play a crucial role. These pathways are tightly regulated, in order to prevent an excessive and sustained immune response, responsible for several pathologies, such as autoimmune and pro-inflammatory diseases. During my PhD thesis, I elucidated some Drosophila regulatory mechanisms of NF-κB pathways, Toll and IMD, which rely on protein ubiquitination and their subsequent degradation by the endocytic pathway or proteasome. Reversible ubiquitination of proteins is a post-translational modification, regulating their activity, their stability and the subcellular localization. In particular, ubiquitination of membrane receptors could trigger their internalization and their subsequent lysosomal degradation. In Drosophila, the PGRP-LC receptor specifically recognizes diaminopimelic acid containing peptidoglycan (PGN) and induces the IMD signaling pathway. I proved that PGRP-LC receptor is ubiquitinated, internalized and degraded by the endocytic pathway. In this process, I identified the major role of the USP8 deubiquitinating enzyme, which controls the degradation of ubiquitinated PGRP-LC. Besides, I showed that the IMD stimulation by PGN enhances the PGRP-LC internalization and its degradation, ensuring receptors elimination once the IMD pathway has been activated. Moreover, I took part to studies, aiming to understand the role of USP2, USP34 and USP36, previously selected by the team as negative regulators of the IMD and/or Toll pathways. In particular, my results showed that USP2 principally acts at the Imd level, allowing for the hydrolysis of its K48 poly-ubiquitin chains and its proteasomal degradation. Finally, I observed that USP2 also interacts with PGRP-LC and favors the hydrolysis of PGRP-LC associated K48 chains, whereas the degradation of K48 poly-ubiquitinated PGRP-LC is independent from the proteasome, but rather depends on the Hrs and Rab5 endocytic proteins and on the USP8 deubiquitinating enzyme.

Thèse numérisée par la Division de la gestion de documents et des archives de l'Université de Montréal

Die Gliazellen des enterischen Nervensystems galten lange Zeit lediglich als Packmaterial der Neuronen. Erst in den letzten Jahren rückte dieser Zelltyp in das Interesse der Forschung, weil mehrere Studien eine Schlüsselrolle bei der Erhaltung der Darmwandintegrität postulierten. Da bisher wenig über die immunphysiologischen Eigenschaften der enterischen Gliazellen bekannt war, wurde in dieser Arbeit deren Bedeutung bei der angeborenen intestinalen Immunantwort untersucht. Hierfür wurden Primärkulturen von enterischen Gliazellen eingesetzt, welche aus dem Plexus myentericus adulter Ratten stammten. Es wurde erstmalig nachgewiesen, dass enterische Gliazellen über Toll like und NOD-Rezeptoren (TLR 2, TLR 4, TLR 6, TLR 7, TLR 9, NOD 1, NOD 2) pathogene bakterielle Muster (PAMPs) erkennen. Dabei zeigte sich, dass eine enge Vernetzung zwischen den Toll-like-Rezeptoren besteht. Einerseits findet eine Liganden-spezifische Regulierung der Toll-like-Rezeptoren statt, anderseits beeinflussen TLR spezifische Liganden die mRNA-Expression weiterer Toll-like-Rezeptoren. In der Analyse der intrazellulären Signalweiterleitung konnte die Existenz verschiedener Adaptor- und Interaktionsmoleküle wie RICK und Myd88 sowie der IKK / NF κB Signalweg mit Degradierung von IκB α nach Aktivierung durch LPS belegt werden. Aktivierte enterische Gliazellen sind eine Quelle für pro- und anti-inflammatorische Interleukine (IL-1α, IL 1β, IL 6, IL-10, IL-12), TNF α und Chemokine (Ccl-2, Cxcl-9, Cxcl-10). Sie können somit weitere immunkompetente Zellen rekrutieren und agieren vermutlich als Schnittstelle zwischen der angeborenen und erworbenen Immunantwort. Die Ergebnisse dieser Arbeit implizieren, dass es sich bei enterischen Gliazellen um einen zusätzlichen immunregulatorischen Zelltyp im Darm handelt, welcher aktiv bei der angeborenen Immunabwehr mitwirkt. Neben pro inflammatorischen Eigenschaften tragen enterische Gliazellen auch zur Darmprotektion während Entzündungsprozessen bei. Daraus ergibt sich eine komplexe Funktionalität der enterischen Gliazellen bei der immunologischen Homöostase im Darm.

FACT est une protéine clé, qui joue de multiples rôles, y compris dans la transcription et la réparation de l'ADN endommagé. Néanmoins, comment FACT participe à la réparation et à la transcription de la chromatine n'est pas élucidé. Dans ce travail nous avons tout d'abord étudié le rôle de FACT dans le processus de réparation par excision de base (BER). Nous avons utilisé des nucléosomes reconstitués avec de l'ADN à uracile incorporé au hasard. Nous avons trouvé que l'enzyme UDG est capable d'enlever les uraciles localisés du côté de la solution et pas les uraciles se trouvant en face de l'octamère d'histone. La présence simultanée de FACT et de RSC (facteur de remodelage de la chromatine, impliqué dans la réparation) permet un enlèvement efficace des uraciles localisés du côté de l'octamère d'histone par l'UDG. De plus, l'action concertée de FACT et RSC contribue à l'enlèvement de la lésion oxidative 8-oxoG, autrement inaccessible, de la matrice nucléosomale par l'enzyme OGG1. Ce résultat est obtenu grâce à une activité « co-remodelatrice » de la protéine FACT. Dans ce travail nous décrivons pour la première fois cette nouvelle propriété de FACT et nous montrons par une série d'expériences biochimiques que FACT est capable de stimuler l'activité de remodelage du RSC. Nos expériences montrent que la présence de FACT augmente l'efficacité de RSC à transformer l'énergie libérée par l'hydrolyse de l'ATP en travail « mécanique ». Les données obtenues suggèrent une nature stochastique du BER in vivo, FACT étant un facteur clé dans le processus de réparation. Nous avons également investigué l'implication de l'activité co-remodelatrice de FACT dans la fixation de NF-kB aux matrices nucléosomales. La production de nucléosomes remodelés, mais non - mobilisés (remosomes) n'est pas suffisante pour promouvoir la fixation de NF-kB. Pourtant, la mobilisation des nucléosomes par l'intermédiaire de RSC permet une interaction efficace entre NF-kB et l'ADN nucléosomal. Toutes ces données sont essentielles pour le décryptage du mécanisme moléculaire par lequel FACT agit dans le BER et dans la transcription médiée par NF-kB. / FACT is a vital protein which has multiple roles including one in transcription and repair of damaged DNA. However, how FACT assists repair and transcription remains elusive. In this work, we have first studied the role of FACT in Base Excision Repair (BER). We used nucleosomes containing DNA with randomly incorporated uracil. We found that the enzyme UDG is able to remove uracils facing the solution and not the uracils facing the histone octamer. The simultaneous presence of FACT and RSC (a chromatin remodeler involved in repair) allows, however, a very efficient removal of uracil facing the histone octamer by UDG. In addition, the concerted action of FACT and RSC permits the removal of the otherwise un-accessible oxidative lesion 8-oxoG from nucleosomal templates by OGG1. This was achieved thanks to the co-remodeling activity of FACT. Here we described for the first time this novel property of FACT and we show in a series of biochemical experiments that FACT is able to boost the remodeling activity of RSC. The experiments reveal that the presence of FACT increases the efficiency of RSC to transform the energy freed by ATP hydrolysis into “mechanical” work. The presented data suggest a stochastic nature of BER functioning in vivo, FACT being a key factor in the repair process. The implication of the co-remodeling activity of FACT in NF-kB factor binding to nucleosomal templates was also investigated. The generation of remodeled, but not mobilized nucleosomes (remosomes), was not sufficient to promote NF-kB binding. However, the RSC-induced nucleosome mobilization allows efficient NF-kB interaction with nucleosomal DNA. Our data are instrumental in deciphering the molecular mechanism of FACT implication in BER and NF-kB mediated transcription.

Diversos neurônios apresentam uma atividade constitutiva de NF-?B, o qual desempenha múltiplas funções fisiológicas, além da modulação de respostas patológicas. A melatonina, hormônio produzido ritmicamente pela glândula pineal na fase de escuro, é também um fator autócrino e parácrino envolvido em múltiplos processos biológicos, sendo que a citoproteção é uma ação de destaque dessa molécula. A melatonina inibe a translocação nuclear do NF-?B e a expressão do seu produto iNOS em modelos de danos celular. No presente trabalho avaliamos se o efeito citoprotetor da melatonina depende do estado de ativação do NF-?B em cultura de células granulares de cerebelo, tendo em vista que essas células apresentam uma atividade basal deste fator de transcrição fundamental para a sobrevivência das células. Além disso, questionamos se essas células em cultura produziriam melatonina e se esta teria algum papel citoprotetor. Testamos a viabilidade da cultura de células granulares de cerebelo de rato (Wistar 7-8 dias de idade) após 24 horas de incubação com melatonina na presença ou ausência de LPS. Em condição basal a melatonina diminuiu a sobrevivência das células e inibiu a morte celular induzida pelo LPS. Este efeito foi compatível com os resultados da ativação do NF-?B e da expressão da iNOS. Na presença do LPS a melatonina bloqueia a indução da translocação nuclear do NF-?B, a expressão da iNOS e a produção de NO. Quando apenas a melatonina foi incubada, observamos uma inibição transiente (15 min.) do NF-?B, seguida por um aumento do conteúdo nuclear do fator de transcrição (60 min.). A expressão da iNOS seguiu o mesmo perfil, ou seja, sofreu uma inibição transiente (30 min.) seguida de um aumento acima do nível basal após 120 minutos de incubação. Portanto, demonstramos que a melatonina afeta de forma diferente a viabilidade de células granulares de cerebelo dependo do contexto em que as células se encontram. Além disso, obtivemos evidências de que essas células expressam a enzima a AA-NAT, e produzem melatonina, que exerce função protetora para a cultura. Desta forma, nossos dados proporcionam uma base mecanicista para a compreensão da influência do contexto celular na resposta à melatonina / Several neurons constitutively express NF-?B, which plays some physiological roles, besides the well-known control of pathological responses. Melatonin, the hormone produced by the pineal gland rhythmically in the dark phase is also an autocrine and paracrine factor of immune competent cells, involved in multiple biological processes and the cytoprotective action is a highlight of this molecule. Melatonin inhibits the nuclear translocation of NF-?B and the expression of iNOS in models of cell damage. The present study evaluated whether the cytoprotective effect of melatonin depends on the state of activation of NF-?B in cultured cerebellar granule cells, given that these cells have a basal activity of this transcription factor essential for cell survival. Moreover, we questioned whether these cells in culture produce melatonin and whether it would have a cytoprotective role. We tested the viability of the rat (7-8 days old Wistar) cerebellar granule cell culture after 24 h incubation with melatonin in the presence or absence of LPS. In basal condition melatonin decreased cell survival while inhibited cell death induced by LPS. These effects were consistent with the results from the activation of NF-?B and the expression of iNOS. In the presence of LPS melatonin blocked the activation of the NF-?B , the expression of iNOS and the production of NO. When only melatonin was incubated, we observed a transient reduction (15 min) of NF-?B nuclear content, followed by an increase of its nuclear content (60 min). The iNOS expression followed the same profile, i.e. undergone a transient inhibition (30 min), followed by an increase above baseline after 120 min of incubation. Therefore, we have demonstrated that melatonin affects differently the viability of cerebellar granule cells depending on the context. Furthermore, we founded evidences that the granule cells in culture express the key enzyme in the synthesis of melatonin, AA-NAT and produce melatonin, which carries protective function for the culture. Our data provide a mechanistic basis for understanding the influence of cell context on the final output response to melatonin

A inibição crônica do óxido nítrico com Nw-nitroargininemethylester (L-NAME), associado à sobrecarga de sal, leva a hipertensão grave, albuminúria, glomeruloesclerose, isquemia glomerular e fibrose intersticial, caracterizando um modelo de doença renal crônica (DRC). Achados anteriores deste laboratório e de outros sugerem que a ativação de pelo menos duas vias da imunidade inata, TLR4/NF-kB e NLRP3/IL-1beta, ocorre em vários modelos experimentais de DRC e que a progressão da lesão renal pode ser atenuada com a inibição destas vias. No presente estudo, investigamos se a ativação da imunidade inata, através da via TLR4/NF-kB ou NLRP3/IL-1beta, está envolvida na patogênese da lesão renal em outro modelo de DRC, o de inibição crônica do NO com sobrecarga de sal. Ratos Munich-Wistar machos adultos receberam sobrecarga de sal (2% Na+ na dieta e 0,5% Na+ na água do bebedouro) e L-NAME (32 mg/Kg/dia) dissolvido na salina do bebedouro (Grupo HS+N) ou tratados com alopurinol (Alo, 36 mg/Kg/dia, v.o), usado como inibidor de NLRP3 (grupo HS+N+Alo) ou tratados com ditiocarbamato de pirrolidina (PDTC, 60 mg/Kg/dia, v.o), um inibidor de NF-kB (Grupo HS+N+PDTC). Após 4 semanas, os ratos HS+N desenvolveram hipertensão arterial, albuminúria e lesão renal, juntamente com inflamação renal, estresse oxidativo e ativação de ambas as vias NLRP3/IL1-beta e TLR4/NF-kB. Alo reduziu o ácido úrico renal e inibiu a via NLRP3/IL-1beta. Esses efeitos foram associados à atenuação da hipertensão arterial, albuminúria e inflamação/fibrose intersticial, mas não à lesão glomerular. O PDTC diminuiu o ácido úrico renal e inibiu as vias NLRP3 e NF-kB, promovendo um efeito antiinflamatório e nefroprotetor mais eficiente que o Alo. As vias NLRP3/IL-1beta e TLR4/NF-kB atuam paralelamente para promover lesão/inflamação renal e devem ser simultaneamente inibidas para obter nefroproteção maior nesse modelo de DRC / Nitric oxide inhibition with Nk-nitroargininemethylester (L-NAME) along with salt overload leads to severe hypertension, albuminuria, glomerulosclerosis, glomerular ischemia and collapse, together with interstitial fibrosis, characterizing a model of chronic kidney disease (CKD). Previous findings of this laboratory and elsewhere suggest that activation of at least two pathways of innate immunity, TLR4/NF-kB and NLRP3 inflammasome/IL-1beta, occurs in several experimental models of CKD, and that progression of renal injury can be slowed with inhibition of these pathways. In the present study, we investigated whether activation of innate immunity, through either the TLR4/NFkB or NLRP3/IL-1beta pathway, is involved in the pathogenesis of renal injury in yet another CKD model, chronic NO inhibition with salt overload. Adult male Munich-Wistar rats receiving L-NAME in drinking water and salt overload (Group HS+N) were treated with Allopurinol (ALLO), used as an NLRP3 inhibitor (Group HS+N+ALLO), or PyrrolidineDithiocarbamate (PDTC) a NF-kB inhibitor (Group HS+N+PDTC). After 4 wks, HS+N rats developed hypertension, albuminuria and renal injury, along with renal inflammation, oxidative stress and activation of both the NLRP3/IL1-beta and TLR4/NF-kB pathways. ALLO lowered renal uric acid and inhibited the NLRP3 pathway. These effects were associated with amelioration of hypertension, albuminuria and interstitial inflammation/fibrosis, but not glomerular injury. PDTC lowered renal uric acid and inhibited both the NLRP3 and NF-kB pathways, promoting a more efficient anti-inflammatory and nephroprotective effect than ALLO. NLRP3/IL-1beta and TLR4/NF-kB act in parallel to promote renal injury/inflammation and must be simultaneously inhibited for best nephroprotection

Le virus T lymphotrope humain de type 1 (HTLV-1, Human T cell Leukemia Virus type 1) est l'agent responsable de la leucémie à cellules T de l'adulte, une prolifération maligne de lymphocytes T CD4+. L'activation constitutive de la voie NF-kB dans les lymphocytes T exprimant la protéine virale Tax s'est révélée primordiale pour la prolifération et la transformation induites par HTLV-1. Selon le modèle classique, Tax agit à deux niveaux de la voie NF-kB. Dans le cytoplasme, Tax active constitutivement le complexe IKK (IKB Kinase) en se liant à sa sous-unité régulatrice NEMO/IKKy. Dans le noyau, Tax interagit directement avec les dimères NF-kB dans des corps nucléaires Tax. L'ubiquitinylation et la SUMOylation de Tax ont été initialement décrites comme nécessaires pour l'activation de la phase cytoplasmique et de la phase nucléaire respectivement. Cependant, les mécanismes régulateurs des modifications post-traductionnelles de Tax restent difficiles à identifier car il n'a pas été possible d'étudier séparément l'ubiquitinylation et la SUMOylation de Tax.Au laboratoire, nous avons généré et caractérisé fonctionnellement un nouveau mutant de Tax qui nous a permis de découpler les rôles de l'ubiquitinylation et de la SUMOylation de Tax. Tax- P79AQ81A est ubiquitinylé de façon quantitativement similaire à Tax mais présente une forte réduction (80%) de SUMOylation. De plus, Tax-P79AQ81A ne forme pas de corps nucléaires. Néanmoins, ces deux défauts ne semblent pas préjudiciables pour la capacité du mutant à activer la voie NF-KB non seulement dans des lignées cellulaires mais également dans des lymphocytes T CD4+ primaires. En parallèle, nous avons montré que les corps nucléaires Tax sont rarement présents dans des lymphocytes T chroniquement infectés par HTLV-1, renforçant l'idée que ces structures ne sont pas requises pour l'activation de la voie NF-KB et probablement pas pour les autres fonctions de Tax. Enfin, nous avons démontré que les capacités d'activation de la voie NF-KB de différents mutants de Tax sont fortement corrélées à leur niveau d'ubiquitinylation mais pas de SUMOylation, confirmant que l'ubiquitinylation de Tax est la modification essentielle pour l'activation de la voie NF-KB.Le virus HTLV-2 ne possède pas les propriétés transformantes du virus HTLV-1 et les propriétés de la protéine Tax2 comparées à celles de Tax1 pourraient être à l'origine des différences de pathogénicité entre les deux virus. Notre étude a révélé que, de façon surprenante, l'activation de la voie NF-KB par la protéine Tax2 est non seulement indépendante de la SUMOylation et de la formation des corps nucléaires comme pour Tax1, mais également indépendante d'une quelconque ubiquitinylation, suggérant des mécanismes différents d'activation du complexe IKK parTax1 et Tax2.Nos études, aussi bien de la protéine Tax1 que de la protéine Tax2, nous ont donc permis de revisiter le modèle actuel d'activation de la voie NF-kB en démontrant l'impact mineur de la SUMOylation et en révélant une différence majeure en ce qui concerne le rôle de l'ubiquitinylation, distinguant les virus HTLV-1 et HTLV-2 / Human T cell Leukemia Virus type 1 (HTLV-1) is the etiological agent of adult T-cell leukemia (ATL), a CD4+ T-cell malignancy, Constitutive activation of the NF-KB pathway plays a crucial role in cell proliferation and transformation induced by HTLV-1, According to the classical model, Tax acts at two levels on the NF-KB pathway, In the cytoplasm, Tax activates the IKB kinase (IKK) complex by directly interacting with the regulatory subunit NEMO/IKKy, In the nucleus, Tax directly interacts with the NF-KB dimers in particular structures named Tax nuclear bodies, Both ubiquitinylation and SUMOylation were initially considered as critical for activation of the cytoplasmic or nuclear phase, respectively, However, the individual role of each modification was difficult to assess because of the lack of molecular tools allowing to study Tax ubiquitination and SUMOylation separately,In the laboratory, we functionally characterized a new Tax mutant, Tax-P 7 9AQ81A, which gave us the opportunity to uncouple Tax ubiquitination and SUMOylation, Indeed, Tax-P79AQ81A is ubiquitinated similarly to wild-type Tax but is severely reduced in SUMOylation, In addition, Tax- P 7 9AQ81A does not form nuclear bodies, However, despite these two severe defects, we found that the mutant is fully able to activate the NF-KB pathway not only in cells lines but also in CD4+ primary T cells, Moreover we showed that Tax nuclear bodies are hardly present in HTLV-1 chronically infected T cell lines, confirming the idea that these structures are not required for Tax-induced NF-KB activation and probably for other Tax functions, Finally, we demonstrated that ability of different Tax mutant to activate the NF-KB pathway is strongly correlated with their ubiquitination but not SUMOylation level, confirming that ubiquitination is the key Tax modification required for activation of the NF-KB pathway,In contrast to HTLV-1, the related HTLV-2 virus is not a transforming virus and therefore, the properties of the Tax2 protein compared to that of Tax1 could be responsible for the different pathogenicity of HTLV-2 and HTLV-1, We studied the post-translational modifications of Tax2 and surprisingly, found that Tax2-induced NF-KB activation is not only independent of SUMOylation and nuclear body formation but also of ubiquitination, suggesting different mechanisms of activation of the IKK complex by Tax1 and Tax2,In conclusion, our results led us to propose a new model for both Tax1- and Tax2-induced NF- KB activation in which SUMOylation has a minor role and in which the requirement of Tax ubiquitination distinguishes between HTLV-1 and HTLV-2